Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

centripetalis recessive dystrophic epidermolysis bullosa - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

centripetalis recessive dystrophic epidermolysis bullosa

MONDO:0019521

Also known as:RDEB, centripetalisRDEB-Cecentripetal dystrophic epidermolysis bullosa

Overview

Centripetalis recessive dystrophic epidermolysis bullosa (RDEB-Ce) is an extremely rare subtype of dystrophic epidermolysis bullosa (DEB), characterized by blistering which begins acrally and then progressively spreads toward the trunk.

Treatments2 FDA approved, newest 2025

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for centripetalis recessive dystrophic epidermolysis bullosa, including Prademagene zamikeracel (zevaskyn, approved 2025) and beremagene geperpavec-svdt (VYJUVEK, approved 2023). An additional 6 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved

Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:35 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:89841

Questions for Your Care Team

→What are the benefits and potential side effects of zevaskyn for managing centripetalis recessive dystrophic epidermolysis bullosa?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
recombinant human type VII pro-collagen	recombinant human type VII pro-collagen	Nova Anchora, LLC	2024	—	Designated
Highly branched poly(beta-amino ester) complexed with a nanoplasmid containing the human COL7A1 gene	Highly branched poly(beta-amino ester) complexed with a nanoplasmid containing the human COL7A1 gene	Amryt Genetics Limited	2020	—	Designated
antisense oligonucleotide targeting exon 73 in the COL7A1 gene	antisense oligonucleotide targeting exon 73 in the COL7A1 gene	Phoenicis Therapeutics, Inc.	2017	—	Withdrawn
autologous genetically modified human dermal fibroblasts	autologous genetically modified human dermal fibroblasts	Castle Creek Biosciences, LLC	2014	—	Designated
recombinant human collagen alpha-1 (VII) chain homo-trimer (rC7)	recombinant human collagen alpha-1 (VII) chain homo-trimer (rC7)	Phoenix Tissue Repair	2014	—	Designated
expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS	expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS	Intercytex Ltd.	2009	—	Designated

Kisho

centripetalis recessive dystrophic epidermolysis bullosa

Overview

Treatment

Approved Therapies

Medical References

External Resources

Orphanet

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

centripetalis recessive dystrophic epidermolysis bullosa

Overview

Treatment

Approved Therapies

Medical References

External Resources

Orphanet

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials